62 related articles for article (PubMed ID: 3116032)
1. Dihydroergocriptine in management of microprolactinomas.
Faglia G; Conti A; Muratori M; Togni E; Travaglini P; Zanotti A; Mailland F
J Clin Endocrinol Metab; 1987 Oct; 65(4):779-84. PubMed ID: 3116032
[TBL] [Abstract][Full Text] [Related]
2. Bromocriptine treatment of microprolactinomas: evidence of stable prolactin decrease after drug withdrawal.
Moriondo P; Travaglini P; Nissim M; Conti A; Faglia G
J Clin Endocrinol Metab; 1985 Apr; 60(4):764-72. PubMed ID: 3919052
[TBL] [Abstract][Full Text] [Related]
3. Long-lasting suppression of prolactin secretion and rapid shrinkage of prolactinomas after a long-acting, injectable form of bromocriptine.
Montini M; Pagani G; Gianola D; Pagani MD; Salmoiraghi M; Ferrari L; Lancranjan I
J Clin Endocrinol Metab; 1986 Jul; 63(1):266-8. PubMed ID: 3711262
[TBL] [Abstract][Full Text] [Related]
4. Prolactinomas resistant to standard dopamine agonists respond to chronic cabergoline treatment.
Colao A; Di Sarno A; Sarnacchiaro F; Ferone D; Di Renzo G; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Mar; 82(3):876-83. PubMed ID: 9062500
[TBL] [Abstract][Full Text] [Related]
5. Effectiveness and tolerability of long term treatment with cabergoline, a new long-lasting ergoline derivative, in hyperprolactinemic patients.
Ciccarelli E; Giusti M; Miola C; Potenzoni F; Sghedoni D; Camanni F; Giordano G
J Clin Endocrinol Metab; 1989 Oct; 69(4):725-8. PubMed ID: 2570790
[TBL] [Abstract][Full Text] [Related]
6. Macroprolactinoma shrinkage during cabergoline treatment is greater in naive patients than in patients pretreated with other dopamine agonists: a prospective study in 110 patients.
Colao A; Di Sarno A; Landi ML; Scavuzzo F; Cappabianca P; Pivonello R; Volpe R; Di Salle F; Cirillo S; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 2000 Jun; 85(6):2247-52. PubMed ID: 10852458
[TBL] [Abstract][Full Text] [Related]
7. Resistance to cabergoline as compared with bromocriptine in hyperprolactinemia: prevalence, clinical definition, and therapeutic strategy.
Di Sarno A; Landi ML; Cappabianca P; Di Salle F; Rossi FW; Pivonello R; Di Somma C; Faggiano A; Lombardi G; Colao A
J Clin Endocrinol Metab; 2001 Nov; 86(11):5256-61. PubMed ID: 11701688
[TBL] [Abstract][Full Text] [Related]
8. Long term therapy of patients with macroprolactinoma using repeatable injectable bromocriptine.
Ciccarelli E; Miola C; Grottoli S; Avataneo T; Lancranjan I; Camanni F
J Clin Endocrinol Metab; 1993 Feb; 76(2):484-8. PubMed ID: 8432794
[TBL] [Abstract][Full Text] [Related]
9. Effect of hydergine in hyperprolactinemia.
Tamura T; Satoh T; Minakami H; Tamada T
J Clin Endocrinol Metab; 1989 Aug; 69(2):470-4. PubMed ID: 2753986
[TBL] [Abstract][Full Text] [Related]
10. Long-term and low-dose treatment with cabergoline induces macroprolactinoma shrinkage.
Colao A; Di Sarno A; Landi ML; Cirillo S; Sarnacchiaro F; Facciolli G; Pivonello R; Cataldi M; Merola B; Annunziato L; Lombardi G
J Clin Endocrinol Metab; 1997 Nov; 82(11):3574-9. PubMed ID: 9360509
[TBL] [Abstract][Full Text] [Related]
11. Dynamics of prolactin secretion in patients with hypopituitarism and pituitary macroadenomas.
Arafah BM; Nekl KE; Gold RS; Selman WR
J Clin Endocrinol Metab; 1995 Dec; 80(12):3507-12. PubMed ID: 8530591
[TBL] [Abstract][Full Text] [Related]
12. Prolactin secretion after surgery or bromocriptine treatment of prolactinoma.
De Leo V; Petraglia F; Sardelli S; Danero S; Genazzani AR; D'Antona N
Obstet Gynecol; 1987 Jan; 69(1):99-103. PubMed ID: 3099236
[TBL] [Abstract][Full Text] [Related]
13. Prolactinomas in children and adolescents. Clinical presentation and long-term follow-up.
Colao A; Loche S; Cappa M; Di Sarno A; Landi ML; Sarnacchiaro F; Facciolli G; Lombardi G
J Clin Endocrinol Metab; 1998 Aug; 83(8):2777-80. PubMed ID: 9709946
[TBL] [Abstract][Full Text] [Related]
14. Bromocriptine treatment reduces the cell size in human macroprolactinomas: a morphometric study.
Bassetti M; Spada A; Pezzo G; Giannattasio G
J Clin Endocrinol Metab; 1984 Feb; 58(2):268-73. PubMed ID: 6693536
[TBL] [Abstract][Full Text] [Related]
15. Long-term treatment of bromocriptine-intolerant prolactinoma patients with CV 205-502.
Glaser B; Nesher Y; Barziliai S
J Reprod Med; 1994 Jun; 39(6):449-54. PubMed ID: 7932398
[TBL] [Abstract][Full Text] [Related]
16. Long term treatment with CV 205-502 in patients with prolactin-secreting pituitary macroadenomas.
Serri O; Beauregard H; Lesage J; Pedneault L; Comtois R; Jilwan N; Somma M; Vachon L; Brownell J
J Clin Endocrinol Metab; 1990 Sep; 71(3):682-7. PubMed ID: 2394774
[TBL] [Abstract][Full Text] [Related]
17. Cabergoline in the treatment of acromegaly: a study in 64 patients.
Abs R; Verhelst J; Maiter D; Van Acker K; Nobels F; Coolens JL; Mahler C; Beckers A
J Clin Endocrinol Metab; 1998 Feb; 83(2):374-8. PubMed ID: 9467544
[TBL] [Abstract][Full Text] [Related]
18. Abnormal LH pulsatility in women with hyperprolactinaemic amenorrhoea normalizes after bromocriptine treatment: deconvolution-based assessment.
Sartorio A; Pizzocaro A; Liberati D; De Nicolao G; Veldhuis JD; Faglia G
Clin Endocrinol (Oxf); 2000 Jun; 52(6):703-12. PubMed ID: 10848874
[TBL] [Abstract][Full Text] [Related]
19. Treatment of macroprolactinomas with the long-acting and repeatable form of bromocriptine: a report on 29 cases.
Beckers A; Petrossians P; Abs R; Flandroy P; Stadnik T; de Longueville M; Lancranjan I; Stevenaert A
J Clin Endocrinol Metab; 1992 Jul; 75(1):275-80. PubMed ID: 1619019
[TBL] [Abstract][Full Text] [Related]
20. Effect of different dopaminergic agents in the treatment of acromegaly.
Colao A; Ferone D; Marzullo P; Di Sarno A; Cerbone G; Sarnacchiaro F; Cirillo S; Merola B; Lombardi G
J Clin Endocrinol Metab; 1997 Feb; 82(2):518-23. PubMed ID: 9024247
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
